Skip to main content
Clinical Trials/NCT05358483
NCT05358483
Recruiting
Not Applicable

The PROMISE Study: PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health

Northwestern University1 site in 1 country1,000 target enrollmentSeptember 7, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infertility, Female
Sponsor
Northwestern University
Enrollment
1000
Locations
1
Primary Endpoint
Live birth after embryo transfer
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of the PROMISE study is to determine how pre-conception lifestyle factors (e.g., sleep, nutrition, physical activity) affect short- and long-term reproductive outcomes.

Detailed Description

The overall goal of the PROMISE study is to identify strategies to improve health outcomes for women and their children. The proposed study is important and novel as it aims to capture women before they are pregnant. Current research on maternal and child health often focuses on women who are already pregnant. This time period is likely too late to make a meaningful clinical impact on long term maternal and child health outcomes influenced by social and epidemiologic determinants of health as important epigenetic changes are or have already taken place. Examples of tools that will be used to capture social and epidemiologic data include validated surveys for nutrition, physical activity, sleep, and stress. The importance of these tools is that many of the data points captured are modifiable, and therefore if associations are noted between these data points and health outcomes, actionable interventions may be developed and implemented for women who are preconceptional.

Registry
clinicaltrials.gov
Start Date
September 7, 2021
End Date
December 2046
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Emily Jungheim

Chief of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology

Northwestern University

Eligibility Criteria

Inclusion Criteria

  • Women ages 18-44 seeking pregnancy at Northwestern Fertility and Reproductive Medicine (FRM) who agree to
  • Be followed for a period for up to 25 years
  • Share information regarding their child's health
  • No prior IVF cycles

Exclusion Criteria

  • Women using donor oocytes or gestational carriers
  • Inability or unwillingness to provide informed consent for any aspects of the study

Outcomes

Primary Outcomes

Live birth after embryo transfer

Time Frame: ~0-24 months

Live birth after embryo transfer (y/n)

Secondary Outcomes

  • Lupus(~12-36 months)
  • Date of delivery(~12-36 months)
  • Time of delivery(~12-36 months)
  • Maternal height at oocyte retrieval(~12-36 months)
  • Maternal weight at last OB visit(~12-36 months)
  • Maternal weight at 1 year postpartum(~12-36 months)
  • Multiple gestation(~12-36 months)
  • Intrauterine growth restriction(~12-36 months)
  • Presentation of spontaneous preterm birth (if applicable)(~12-36 months)
  • AMH(~0-24 months)
  • PGT indication(~0-24 months)
  • Stimulation type(~0-24 months)
  • Number of oocytes retrieved(~0-24 months)
  • Antral follicle count (AFC)(~0-24 months)
  • Maximum estradiol level (pmol/L)(~0-24 months)
  • Cycle cancellation(~0-24 months)
  • Number of embryos transferred(~0-24 months)
  • Type of embryo transfer(~0-24 months)
  • Ovarian hyperstimulation syndrome(~0-24 months)
  • Clinical outcome(~0-24 months)
  • Abruption(~12-36 months)
  • Cycle number(~0-24 months)
  • Diagnosis/reason for ART(~0-24 months)
  • Days of stimulation(~0-24 months)
  • Number of embryos cryopreserved(~0-24 months)
  • Stage of embryo cryopreservation(~0-24 months)
  • Endometrial thickness(~0-24 months)
  • Singleton pregnancy(~12-36 months)
  • Insulin(~12-36 months)
  • Asthma(~12-36 months)
  • Total gonadotropin dose (IU/L)(~0-24 months)
  • Trigger type(~0-24 months)
  • Number of blastocysts(~0-24 months)
  • Day of embryo transfer(~0-24 months)
  • Frozen embryo transfer protocol(~0-24 months)
  • Luteal phase support(~0-24 months)
  • PGT(~0-24 months)
  • Sperm source(~0-24 months)
  • Number follicles >14 mm(~0-24 months)
  • Number of mature oocytes(~0-24 months)
  • Grade of embryo transferred(~0-24 months)
  • PGT methodology(~0-24 months)
  • Insemination Type(~0-24 months)
  • Gestational hypertension/pre-eclampsia(~12-36 months)
  • Renal disease(~12-36 months)
  • Length of NICU stay(~12-48 months)
  • Maternal weight at oocyte retrieval(~12-36 months)
  • Neonatal death(~12-48 months)
  • Prenatal genetic testing(~12-36 months)
  • Type of prenatal genetic testing(~12-36 months)
  • Polyhydramnios(~12-36 months)
  • Number of mature oocytes inseminated(~0-24 months)
  • Weight at delivery(~12-36 months)
  • Mode of delivery(~12-36 months)
  • Length of hospital stay(~12-36 months)
  • Large-for-gestational age(~12-36 months)
  • Breastfeeding at 1 year of life(~12-48 months)
  • Gestational diabetes(~12-36 months)
  • Placental disorders(~12-36 months)
  • Heart disease(~12-36 months)
  • Predelivery hospitalization(~12-36 months)
  • Maternal weight at embryo transfer(~12-36 months)
  • Spontaneous preterm birth(~12-36 months)
  • Tocolytic medication during pregnancy(~12-36 months)
  • Presentation of term birth (if applicable)(~12-36 months)
  • Postpartum weight change(~12-48 months)
  • Child height at 1 year of life(~12-48 months)
  • Congenital malformation(~12-36 months)
  • Thyroid disease(~12-36 months)
  • Pregnancy COVID vaccination(~12-36 months)
  • Number of mature oocytes fertilized (2PN)(~0-24 months)
  • Preterm birth(~12-36 months)
  • Intrapartum antibiotics(~12-36 months)
  • Head circumference(~12-36 months)
  • Infection(~12-36 months)
  • 5-min APGAR score(~12-36 months)
  • Supplemental formula(~12-48 months)
  • Clinical chorioamnionitis(~12-36 months)
  • Maternal blood type(~12-36 months)
  • Preconception COVID vaccination(~12-36 months)
  • Gestational age at delivery(~12-36 months)
  • Magnesium sulfate administered(~12-36 months)
  • Antepartum hemorrhage(~12-36 months)
  • Postpartum hemorrhage(~12-36 months)
  • Birthweight(~12-36 months)
  • Small-for-gestational age(~12-36 months)
  • Arterial umbilical cord pH(~12-36 months)
  • Breastfeeding compliance(~12-48 months)
  • Maternal mortality(~12-36 months)
  • Anesthetic complication(~12-36 months)
  • Blood transfusion(~12-36 months)
  • Thromboembolism(~12-36 months)
  • 1-min APGAR score(~12-36 months)
  • General well-being(~12-48 months)
  • Breastfeeding(~12-48 months)
  • NICU admission(~12-48 months)
  • Child weight at 1 year of life(~12-48 months)

Study Sites (1)

Loading locations...

Similar Trials